Skip to main content
  • Register
  • Help
  • Contact us

Humanigen Inc (HGEN) USD0.001

Sell:$19.22 Buy:$19.36 Change: $0.96 (5.22%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$19.22
Buy:$19.36
Change: $0.96 (5.22%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$19.22
Buy:$19.36
Change: $0.96 (5.22%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Humanigen, Inc., formerly KaloBios Pharmaceuticals, Inc., is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company's product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems. It is engaged in developing monoclonal antibodies, lenzilumab, for the treatment of chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia both of which are rare hematologic cancers. It is exploring development of another of its monoclonal antibodies, ifabotuzumab, for the treatment of rare solid and hematologic cancers. Its KB001-A, is a Humaneered, PEGylated, anti-PcrV modified antibody fragment (Fab) antibody developed for the prevention and treatment of Pseudomonas aeruginosa (Pa), and infections in mechanically ventilated patients and cystic fibrosis (CF).

Contact details

Address:
533 Airport Blvd Ste 400
BURLINGAME
94010-2013
United States
Telephone:
+1 (650) 2433100
Website:
https://www.humanigen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HGEN
ISIN:
US4448632038
Market cap:
$1.12 billion
Shares in issue:
58.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Cameron Durrant
    Chairman of the Board, Chief Executive Officer
  • Timothy Morris
    Chief Financial Officer, Chief Operating Officer, Chief Accounting and Administrative Officer
  • Omar Ahmed
    Senior Vice President - Clinical, Medical and Scientific Affairs
  • Dale Chappell
    Chief Scientific Officer, Director
  • Edward Jordan
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.